Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.
Dexrazoxane has cardioprotective properties that can prevent long-term cardiotoxicity in pediatric patients receiving chemotherapy, according to a review of the medical literature on cardiotoxic effects of anthracycline treatment.
Trastuzumab-related cardiotoxicity was far lower in Taiwanese women with breast cancer compared with previously published results, according to recent study data.
A study examined the relation between various forms of breast cancer therapies and risk of congestive heart failure.
Breast cancer patients with BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|